Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC - Trauner, M; Bowlus, C L; Gulamhusein, A (Clin Gastroenterol Hepatol, 2023)